CebaracetamAlternative Names: CGS 25248; ZY 15119
Latest Information Update: 23 May 1995
At a glance
- Originator Novartis Consumer Health
- Class Nootropics; Piperazines; Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cognition disorders
Most Recent Events
- 23 May 1995 Discontinued-II for Cognition disorders in Switzerland (Unknown route)